AstraZeneca taps Emergent as U.S. partner for potential COVID-19 vaccine

AstraZeneca Plc on Thursday picked Emergent BioSolutions Inc to help produce the 300 million doses of the British drugmaker's potential COVID-19 vaccine pledged to the United States.